Quick Take
IDEAYA Biosciences (IDYA) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on the discovery and development of cancer therapeutics.
IDYA is in Phase 1/2 trials (run by Novartis) for its lead candidate and the firm has a large and capable investor base, which includes Roche.
Company & Technology
San Francisco, California-based IDEAYA was founded in 2015 to discover and develop therapeutics for the treatment of oncological diseases.
Management is headed by Founder, President, and CEO